Compare TG Therapeutics Inc (TGTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Union Pacific Corporation — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Union Pacific Corporation trades at $285.05 (market cap $171.36B). The key difference: Union Pacific Corporation is far larger — about 20.1× TG Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.97% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UNP | |
|---|---|---|
Market Cap | $8.53B | $171.36B |
Sector | Health | Industrials |
52-Week High | $59.06 | $310.62 |
52-Week Low | $26.94 | $214.91 |
Enterprise Value | $8.74B | $200.42B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Union Pacific (UNP) trades at $288.45, down 0.4% on the day, with a bearish technical signal but strong fundamentals including a 28.85% net income margin and robust cash flow. Recent earnings beats in Q1 and Q2 2026, coupled with a pending Norfolk Southern merger expected to close by late 2027, highlight growth potential. The stock is supported by a consensus analyst price target of $334.33, indicating 16% upside.
The outlook is positive due to solid profitability and merger prospects, but risks include regulatory hurdles for the merger and economic sensitivity. Analysts are predominantly bullish (58.7% buy ratings), though technical indicators suggest near-term caution with support at $287.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
